Abstract
Breast cancer (BC) is one of the most prevalent malignancies throughout the world. Important therapeutic progress has been achieved over the past decade, and the identification of genomic alterations in the homologous recombination repair (HRR) pathway sensitizes tumors to therapeutics such as PARP inhibitors and platinum-based chemotherapy. Here we evaluated the characteristics of HRR related gene mutations in patients with different molecular subtypes of BC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
